Robert J. Gould, President & CEO at Epizyme, Inc. (EPZM), sold 60,000 shares at $23.07 ($1.4M) on 2015-07-06, disclosed to the SEC on 2015-07-08.
Scheduled sale ($1.4M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.07 | 44,858 | $1.0M | 74.3% |
| 2 | $23.64 | 15,142 | $358K | 25.7% |
| Total | $23.21 avg | 60,000 | $1.4M | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |